240 related articles for article (PubMed ID: 24772484)
1. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.
Baker DJ; Atkinson AM; Wilkinson GP; Coope GJ; Charles AD; Leighton B
Br J Pharmacol; 2014 Apr; 171(7):1629-41. PubMed ID: 24772483
[TBL] [Abstract][Full Text] [Related]
3. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
[TBL] [Abstract][Full Text] [Related]
4. Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activation.
Doliba NM; Fenner D; Zelent B; Bass J; Sarabu R; Matschinsky FM
Diabetes Obes Metab; 2012 Oct; 14 Suppl 3(0 3):109-19. PubMed ID: 22928571
[TBL] [Abstract][Full Text] [Related]
5. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
De Ceuninck F; Kargar C; Ilic C; Caliez A; Rolin JO; Umbdenstock T; Vinson C; Combettes M; de Fanti B; Harley E; Sadlo M; Lefèvre AL; Broux O; Wierzbicki M; Fourquez JM; Perron-Sierra F; Kotschy A; Ktorza A
Br J Pharmacol; 2013 Jan; 168(2):339-53. PubMed ID: 22925001
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
7. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
[TBL] [Abstract][Full Text] [Related]
8. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
Fyfe MC; White JR; Taylor A; Chatfield R; Wargent E; Printz RL; Sulpice T; McCormack JG; Procter MJ; Reynet C; Widdowson PS; Wong-Kai-In P
Diabetologia; 2007 Jun; 50(6):1277-87. PubMed ID: 17415548
[TBL] [Abstract][Full Text] [Related]
9. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Tsumura Y; Tsushima Y; Tamura A; Hasebe M; Kanou M; Kato H; Kobayashi T
PLoS One; 2017; 12(2):e0172252. PubMed ID: 28207836
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
11. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
Li W; Zhang X; Sun Y; Liu Z
Pharmazie; 2020 Jun; 75(6):230-235. PubMed ID: 32539915
[TBL] [Abstract][Full Text] [Related]
12. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
Deshpande AM; Bhuniya D; De S; Dave B; Vyavahare VP; Kurhade SH; Kandalkar SR; Naik KP; Kobal BS; Kaduskar RD; Basu S; Jain V; Patil P; Chaturvedi Joshi S; Bhat G; Raje AA; Reddy S; Gundu J; Madgula V; Tambe S; Shitole P; Umrani D; Chugh A; Palle VP; Mookhtiar KA
Eur J Med Chem; 2017 Jun; 133():268-286. PubMed ID: 28390958
[TBL] [Abstract][Full Text] [Related]
13. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
[TBL] [Abstract][Full Text] [Related]
14. Novel glucokinase activators: a patent review (2008 - 2010).
Sarabu R; Berthel SJ; Kester RF; Tilley JW
Expert Opin Ther Pat; 2011 Jan; 21(1):13-33. PubMed ID: 21155690
[TBL] [Abstract][Full Text] [Related]
15. Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats.
Coope GJ; Atkinson AM; Allott C; McKerrecher D; Johnstone C; Pike KG; Holme PC; Vertigan H; Gill D; Coghlan MP; Leighton B
Br J Pharmacol; 2006 Oct; 149(3):328-35. PubMed ID: 16921397
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of β-cell genes and improved function in rodent islets following chronic glucokinase activation.
Gill D; Brocklehurst KJ; Brown HW; Smith DM
J Mol Endocrinol; 2011 Aug; 47(1):59-67. PubMed ID: 21571864
[TBL] [Abstract][Full Text] [Related]
17. Allosteric activators of glucokinase: potential role in diabetes therapy.
Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.
Futamura M; Yao J; Li X; Bergeron R; Tran JL; Zycband E; Woods J; Zhu Y; Shao Q; Maruki-Uchida H; Goto-Shimazaki H; Langdon RB; Erion MD; Eiki J; Zhou YP
Diabetologia; 2012 Apr; 55(4):1071-80. PubMed ID: 22234649
[TBL] [Abstract][Full Text] [Related]
20. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
